Tadalafil
- Product NDC
- 68788-8153
- 11-digit product format
- 687888153
- Labeler code
- 68788
- Product ID
- 68788-8153_4677fe18-0da6-4c0e-989a-d77e4f228a58
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Tadalafil
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Preferred Pharmaceuticals Inc.
- Application
- ANDA209167
- Marketing category
- ANDA
- Marketing start
- 2022-03-14
- Substance
- TADALAFIL
- Active strength
- 20 mg/1
- Pharmacologic classes
- Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209167-001 | TADALAFIL | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2019-03-26 | |
| A209167-002 | TADALAFIL | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2019-03-26 | |
| A209167-003 | TADALAFIL | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2019-10-23 | |
| A209167-004 | TADALAFIL | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2019-03-26 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209167-001 | AB1 |
| A209167-002 | AB1 |
| A209167-003 | AB1 |
| A209167-004 | AB1 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209167-001 | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209167-002 | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209167-003 | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2019-10-23 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209167-004 | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209167-001 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209167-002 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209167-003 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209167-004 | AB1 | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | 07567ae5-7345-4ab1-9b2c-c586c4da0427 | 2026-06-24 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | aa8d165b-0c7d-497a-b56a-7c62ebc0a5d2 | 2026-05-13 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | f8def23c-55ea-4796-9735-dbcb25104835 | 2026-05-13 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Accord Healthcare Inc. | eedf3ad9-7d40-496d-b1a9-6200010c18e1 | 2026-04-16 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | affacb88-4af3-4ce9-961b-7fc37b169e9a | 2026-01-12 | Warnings, Adverse reactions | 209167 ANDA209167 68788-8153 |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | f3092f5a-b976-91ab-e053-2995a90a9b50 | 2026-01-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | f317fe1e-d7c4-fb8b-e053-2a95a90a5445 | 2026-01-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | cf35291b-b05b-1182-e053-2995a90a8dee | 2025-02-10 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | 9f83ea2e-8ee8-ab6d-e053-2995a90a1e96 | 2024-06-20 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | a0acad71-8ae3-2827-e053-2995a90a20b3 | 2024-06-20 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | 7a105ef9-7129-4ce1-bd8d-ae316bf348e2 | 2022-11-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | b539e862-d5d4-4989-a3dd-1eba66285d53 | 2022-05-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | 31c05a53-7282-46d0-81bd-108defe6fb38 | 2022-04-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | 6fa9d4fa-86c9-4791-b28b-78e8b9341cea | 2022-04-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Asclemed USA, Inc. | aba646fe-70c2-1abb-e053-2995a90aa16d | 2022-01-28 | Warnings, Adverse reactions | 209167 ANDA209167 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Tadalafil
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| TADALAFIL | 20 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 742SXX0ICT | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 402019 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| affacb88-4af3-4ce9-961b-7fc37b169e9a | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| b90b74cb-f6c8-3798-d11c-73b8768b278a | Product name | 8 | 20250317 |
| 0fe0157c-95a7-4870-ae64-de9f3fa874ae | Product name | 1 | 20250227 |
| 20ae0006-d78c-4dba-9e3e-6ae424841903 | Product name | 1 | 20250127 |
| b86a08b7-54cc-440b-ad4a-3e530ccd8324 | Product name | 6 | 20230421 |
| 7a02e74a-2844-42af-84a8-96bae57351cf | Product name | 1 | 20230313 |
| 928d249c-35c3-4d88-a9ef-cf2f2e31b96f | Product name | 1 | 20220706 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68788-8153-7 | Tadalafil | 7 in 1 BOTTLE | TABLET, FILM COATED | 7 | 5 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68788-8153-7 | EA - Each | 68788-8153 | e1c1dbff-8f04-464d-8d87-c4692f79edda | 1 | 2022-04-06 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68788-8153 | TADALAFIL TABLET, FILM COATED [PREFERRED PHARMACEUTICALS INC.] | 3 | Current NDC, Legacy NDC, 1 package rows | 20240816_affacb88-4af3-4ce9-961b-7fc37b169e9a.zip |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 402019 | tadalafil 20 MG Oral Tablet | PSN | affacb88-4af3-4ce9-961b-7fc37b169e9a | 5 |
| 402019 | tadalafil 20 MG Oral Tablet | SCD | affacb88-4af3-4ce9-961b-7fc37b169e9a | 5 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 68788-8153-7 | 68788815307 | 7 TABLET, FILM COATED in 1 BOTTLE (68788-8153-7) | 2022-03-14 | 0000-00-00 | No | No | Current |